Title | SARS-CoV-2 infection induces beta cell transdifferentiation. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Tang X, Uhl S, Zhang T, Xue D, Li B, J Vandana J, Acklin JA, Bonnycastle LL, Narisu N, Erdos MR, Bram Y, Chandar V, Chong AChi Nok, Lacko LA, Min Z, Lim JK, Borczuk AC, Xiang J, Naji A, Collins FS, Evans T, Liu C, tenOever BR, Schwartz RE, Chen S |
Journal | Cell Metab |
Volume | 33 |
Issue | 8 |
Pagination | 1577-1591.e7 |
Date Published | 2021 Aug 03 |
ISSN | 1932-7420 |
Keywords | Acetamides, Adolescent, Adult, Aged, Aged, 80 and over, Animals, Cell Transdifferentiation, Chlorocebus aethiops, COVID-19, Cyclohexylamines, Cytokines, Eukaryotic Initiation Factor-2, Female, Glucagon, Host-Pathogen Interactions, Humans, Insulin, Insulin-Secreting Cells, Male, Middle Aged, Phenotype, SARS-CoV-2, Signal Transduction, Tissue Culture Techniques, Trypsin, Vero Cells, Young Adult |
Abstract | <p>Recent clinical data have suggested a correlation between coronavirus disease 2019 (COVID-19) and diabetes. Here, we describe the detection of SARS-CoV-2 viral antigen in pancreatic beta cells in autopsy samples from individuals with COVID-19. Single-cell RNA sequencing and immunostaining from ex vivo infections confirmed that multiple types of pancreatic islet cells were susceptible to SARS-CoV-2, eliciting a cellular stress response and the induction of chemokines. Upon SARS-CoV-2 infection, beta cells showed a lower expression of insulin and a higher expression of alpha and acinar cell markers, including glucagon and trypsin1, respectively, suggesting cellular transdifferentiation. Trajectory analysis indicated that SARS-CoV-2 induced eIF2-pathway-mediated beta cell transdifferentiation, a phenotype that could be reversed with trans-integrated stress response inhibitor (trans-ISRIB). Altogether, this study demonstrates an example of SARS-CoV-2 infection causing cell fate change, which provides further insight into the pathomechanisms of COVID-19.</p> |
DOI | 10.1016/j.cmet.2021.05.015 |
Alternate Journal | Cell Metab |
PubMed ID | 34081913 |
PubMed Central ID | PMC8133495 |
Grant List | DP3 DK111907 / DK / NIDDK NIH HHS / United States ZIA HG000024 / ImNIH / Intramural NIH HHS / United States R01 DK119667 / DK / NIDDK NIH HHS / United States R01 CA234614 / CA / NCI NIH HHS / United States R01 DK124463 / DK / NIDDK NIH HHS / United States R03 DK117252 / DK / NIDDK NIH HHS / United States R01 DK116075 / DK / NIDDK NIH HHS / United States UC4 DK112217 / DK / NIDDK NIH HHS / United States R01 AI107301 / AI / NIAID NIH HHS / United States F32 HD096810 / HD / NICHD NIH HHS / United States U01 DK127777 / DK / NIDDK NIH HHS / United States P30 DK020541 / DK / NIDDK NIH HHS / United States R01 DK121072 / DK / NIDDK NIH HHS / United States P60 DK020541 / DK / NIDDK NIH HHS / United States |